These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24461741)

  • 1. [Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
    Barea Mendoza JA; Gredilla Zubiría I; González Olmedo J; Mateo Alvarez S
    Med Clin (Barc); 2014 Sep; 143(6):284-5. PubMed ID: 24461741
    [No Abstract]   [Full Text] [Related]  

  • 2. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
    Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
    J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
    [No Abstract]   [Full Text] [Related]  

  • 3. Case report: A rare cause of severe hypophosphatemia.
    Román-Gimeno S; Ortez-Toro JJ; Peteiro-Miranda CM; Sanz-Martín B; Urdaniz-Borque R
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):125-126. PubMed ID: 32409006
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphorus levels in children treated with intravenous ferric carboxymaltose.
    Kirk SE; Scheurer ME; Bernhardt MB; Mahoney DH; Powers JM
    Am J Hematol; 2021 Jun; 96(6):E215-E218. PubMed ID: 33735470
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.
    Amarnani R; Travis S; Javaid MK
    Rheumatology (Oxford); 2020 Aug; 59(8):2166-2168. PubMed ID: 31930323
    [No Abstract]   [Full Text] [Related]  

  • 6. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
    Sánchez González R; Ternavasio-de la Vega HG; Moralejo Alonso L; Inés Revuelta S; Fuertes Martín A
    Med Clin (Barc); 2015 Aug; 145(3):108-11. PubMed ID: 25579771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric carboxymaltose (Injectafer) for iron deficiency anemia.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):99-100. PubMed ID: 24322665
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravenous iron among cystic fibrosis patients.
    Hoo ZH; Wildman MJ
    J Cyst Fibros; 2012 Dec; 11(6):560-2. PubMed ID: 22717534
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
    Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
    Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron supplementation in a case of severe iron deficiency anaemia.
    Füllenbach C; Triphaus C; Glaser P; Ziebart A; Zacharowski K; Meybohm P; Choorapoikayil S
    Br J Anaesth; 2018 Aug; 121(2):502-504. PubMed ID: 30032895
    [No Abstract]   [Full Text] [Related]  

  • 17. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient.
    Mani LY; Nseir G; Venetz JP; Pascual M
    Transplantation; 2010 Oct; 90(7):804-5. PubMed ID: 20881582
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
    Dashwood A; Vale C; Laher S; Chui F; Hay K; Wong YW
    J Clin Pharmacol; 2021 Apr; 61(4):515-521. PubMed ID: 33051909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral iron therapy and phosphorus homeostasis: A review.
    Kalantar-Zadeh K; Ganz T; Trumbo H; Seid MH; Goodnough LT; Levine MA
    Am J Hematol; 2021 May; 96(5):606-616. PubMed ID: 33471363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.